Thiamine: Nursing Drug Guide, Wernicke Prevention & NCLEX Review

Thiamine is listed generically on most inpatient orders. Product labels may read thiamine, thiamin, vitamin B1, or thiamine hydrochloride.

Single-entity products include oral thiamine tablets (commonly 50–100 mg per DailyMed listings) and thiamine hydrochloride injection 100 mg/mL (Fresenius Kabi and other manufacturers). Thiamine also appears in multivitamin tablets, B-complex formulations, prenatal vitamins, and parenteral multivitamin injections—duplicate replacement is common when nurses do not reconcile every source.

Thiamine (vitamin B1) supports carbohydrate metabolism as a cofactor for decarboxylation reactions. Nurses most often give it for deficiency prevention or treatment in patients with alcohol use disorder, malnutrition, hyperemesis, or before/with IV dextrose in at-risk admissions.

↔On a small screen, swipe or scroll sideways to see the full table.

Thiamine combines with ATP to form thiamine pyrophosphate (cocarboxylase), a coenzyme for decarboxylation of pyruvic acid and α-ketoacids in carbohydrate metabolism. When thiamine is depleted, pyruvic acid accumulates—nursing relevance: glucose loads in deficient patients increase metabolic demand for thiamine, which is why thiamine timing with dextrose matters clinically. Thiamine also supports activation pathways linked to other B vitamins such as pyridoxine.

Dosing depends on indication (maintenance, beriberi, Wernicke encephalopathy, or co-administration with IV dextrose). Dosing must be verified against current prescribing information, prescriber order, and local policy.

Protocol note: Some emergency and neurology protocols use higher-dose IV thiamine for suspected Wernicke encephalopathy than the label-based examples below. Follow local protocol and the prescriber order; this page lists label-based dosing examples and nursing sequencing priorities (thiamine before or with dextrose in at-risk patients).

Missed dose: Not specified in the reviewed prescribing information for thiamine injection. For scheduled oral supplementation, take the next dose at the usual time—do not double unless prescriber directs.

Pretreatment checks

• Screen for chronic alcohol use, alcoholic hepatitis, malnutrition, hyperemesis, or poor PO intake that increases Wernicke risk
• Complete medication reconciliation—include multivitamins, B-complex, and enteral formulas containing thiamine
• Confirm allergy history to thiamine or formulation excipients; review whether IV dextrose is ordered or running and whether thiamine is sequenced appropriately

Contraindications

• History of sensitivity to thiamine or any ingredient in the specific product (Fresenius Kabi DailyMed)
• Not specified in the reviewed prescribing information beyond hypersensitivity
• Positive intradermal test dose or prior anaphylaxis to parenteral thiamine—do not administer IM/IV without prescriber and allergy specialist guidance

Important interactions

↔On a small screen, swipe or scroll sideways to see the full table.

Route: Oral tablet or capsule for supplementation and maintenance; thiamine hydrochloride injection 100 mg/mL for IM or slow IV administration when rapid restoration is required (Fresenius Kabi DailyMed).

• Oral: standard tablet/capsule administration per product labeling; use safe medication administration when patient can absorb and tolerate PO intake
• IM: 10–20 mg for beriberi per labeling; observe for hypersensitivity especially with repeated injections
• IV: administer slowly using pump-controlled infusion per institutional policy; wet beriberi with myocardial failure is an emergency cardiac situation requiring slow IV thiamine (DailyMed)

• Gradual improvement in confusion, ataxia, and neuropathic symptoms when Wernicke/beriberi is treated early—delayed treatment may leave permanent deficits (NIH ODS)
• Cardiovascular stabilization in wet beriberi when thiamine is administered slowly IV in myocardial failure contexts (DailyMed)
• Prevention of heart failure precipitation when thiamine accompanies early IV dextrose in marginally replete patients per labeling

↔On a small screen, swipe or scroll sideways to see the full table.

↔On a small screen, swipe or scroll sideways to see the full table.

Fresenius Kabi labeling states parenteral doses of 100 to 500 mg singly have been administered without toxic effects, but dosages exceeding 30 mg three times a day are not utilized effectively. Excess thiamine is largely excreted in urine when tissues are saturated.

Overdose signs

• Not specified in the reviewed prescribing information as a distinct overdose syndrome for thiamine alone at usual replacement doses
• Very large parenteral exposures may present as intensified hypersensitivity rather than organ-specific toxicity

Antidote

No specific antidote is listed in the reviewed prescribing information; management is supportive and guided by poison control or toxicology services per facility protocol and local emergency guidance. Treat anaphylaxis per emergency protocol when parenteral reactions occur.

• Thiamine vs other B vitamins—riboflavin (B2), niacin (B3), vitamin B6, and cyanocobalamin (B12) are often co-ordered in “vitamin cocktail” regimens—read the vial and MAR line carefully
• Thiamine 100 mg/mL injection vs multivitamin injection—standalone thiamine vials (100 mg/mL) differ from multivitamin ampules that contain multiple vitamins at lower concentrations
• “Vitamin B1” vs “B-complex”—B-complex and enteral formulas already contain thiamine; duplicate replacement may occur without prescriber intent
• IV push vs slow IV—rapid IV injection is associated with severe reactions per international labeling summaries; use slow IV administration per product labeling and institutional policy
• Thiamine before dextrose sequencing—the highest-stakes “order error” is giving IV dextrose alone to a thiamine-depleted patient when thiamine is available but delayed

No specific ISMP look-alike/sound-alike pair was identified in the reviewed sources beyond general B-vitamin naming overlap, but independent double-check of product name, strength (100 mg/mL), and route still applies.

↔On a small screen, swipe or scroll sideways to see the full table.

Thiamine replacement is often urgent—yet parenteral administration can itself trigger catastrophe. Escalate neurologic deterioration and anaphylaxis immediately; do not attribute acute confusion solely to intoxication without assessing thiamine status.

• New or worsening confusion, ataxia, ophthalmoplegia, or memory disturbance in an at-risk patient—suspect Wernicke even if glucose is normalizing
• Urticaria, angioedema, bronchospasm, hypotension, or collapse during or immediately after IM/IV thiamine—stop and treat per anaphylaxis protocol
• Signs of wet beriberi (tachycardia, edema, respiratory distress) in a malnourished patient—slow IV thiamine is emergency treatment per labeling
• IV dextrose started or bolus given without thiamine in a patient with alcohol use disorder or prolonged poor intake—notify prescriber/pharmacist immediately
• Persistent vomiting preventing oral repletion when only PO vitamins are ordered—clarify need for parenteral route

↔On a small screen, swipe or scroll sideways to see the full table.

Monitor

• Mental status, gait, coordination, and cranial nerve findings (Wernicke surveillance)
• Vitals and respiratory status during and after parenteral doses (anaphylaxis surveillance)
• Basic metabolic panel and intake trends when refeeding malnourished patients—coordinate thiamine with glucose management

Document

• Dose, route, time, indication (Wernicke, beriberi, dextrose co-administration, maintenance)
• Thiamine–dextrose sequencing, allergy status, and observation period after parenteral doses when required
• Neurologic baseline and follow-up assessments; prescriber/pharmacist notifications for hold or reaction

• Explain why thiamine is given before or with IV fluids containing sugar in high-risk admissions
• Oral maintenance: take as directed with balanced nutrition; do not skip because you feel better once acute symptoms improve
• Report rash, swelling, trouble breathing, or feeling of throat tightness immediately after injections or infusions
• Alcohol cessation and dietitian follow-up are part of long-term recovery—not replaced by a single vitamin dose
• Do not add extra B-complex or multivitamin products from home without checking with the care team

Do not give and contact the prescriber/pharmacist when:

Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.

Rehearse NCLEX-style clinical judgment practice for thiamine using a tabbed ED case (MAR, labs, vitals, nursing notes), then priority sequencing before dextrose, Wernicke cue recognition, neuro trend interpretation, matrix urgency sorting, hold-rule judgment, and labeled dextrose co-administration cloze—recognise cues → analyse glucose–thiamine timing → prioritise neurologic safety → evaluate outcomes.

This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.

• Editorial Policy
• Medical Review Process
• Disclaimer

Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.